Overview

Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Sarepta Therapeutics
Sarepta Therapeutics, Inc.
Collaborator:
United States Department of Defense
Criteria
Inclusion Criteria:

- Male or female and between the ages of 18 and 50 years in good general health

- Volunteers must be willing to use barrier methods of contraception or be of
non-childbearing potential

- Volunteers must be willing to undergo a urine screen for drugs of abuse

Exclusion Criteria:

- Pregnancy or breastfeeding.

- Any clinically relevant abnormalities in physical examinations, vital signs, ECG,
clinical chemistry, hematology or urinalysis

- Positive test for human immunodeficiency virus, hepatitis B or hepatitis C or known
history of HIV infection